Besides, employing a non-IL-2 blocking anti-CD25 antibody, Tregs can be eliminated while retaining the responsiveness of effector T cells to IL-2 signaling, thus amplifying the proliferation and function of anti-tumor T cells (142). This evidence concerns the gene IL2 and neoplasm.